SILO (SILO Pharma) Total Stockholders Equity: $4.89 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SILO SILO Pharma Inc SILO
42 GF Score
Price $2.10
GF Value $3.44
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is SILO Pharma Total Stockholders Equity?

SILO Pharma SILO 42 Total Stockholders Equity is $4.89 Mil as of Jun. 2026. GuruFocus rates SILO with a GF Score™ of 42/100 and a GF Value™ of $3.44 (Possible Value Trap). The stock has 3 warning signs investors should review.

SILO Pharma's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $4.89 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. SILO Pharma's Book Value per Share for the quarter that ended in Jun. 2026 was $4.33. The ratio of a company's debt over equity can be used to measure how leveraged this company is. SILO Pharma's Debt-to-Equity for the quarter that ended in Jun. 2026 was 0.00.

SILO Pharma  (NAS:SILO) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

SILO Pharma's Book Value per Share for the quarter that ended in Jun. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(4.886-0)/1.129
=4.33

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

SILO Pharma's Debt-to-Equity for the quarter that ended in Jun. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 4.886
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SILO Pharma Total Stockholders Equity Related Terms

SILO Pharma Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for SILO Pharma's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SILO Pharma Total Stockholders Equity Chart

SILO Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.06 10.34 6.18 5.03 6.31

SILO Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.92 5.01 6.31 5.68 4.89
SILO
42GF Score
SILO Pharma Inc SILO
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $4.89 Mil mean?
SILO Pharma (SILO) has a Total Stockholders Equity of $4.89 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for SILO Pharma and its competitors.
Is SILO Pharma's Total Stockholders Equity too high?
SILO Pharma's current Total Stockholders Equity is $4.89 Mil. Overall, SILO Pharma has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does SILO Pharma's Total Stockholders Equity compare to ELAB and GLMD?
SILO Pharma's Total Stockholders Equity of $4.89 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for SILO Pharma and its competitors. SILO Pharma's current Total Stockholders Equity is $4.89 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SILO Pharma stock overvalued right now?
Based on GuruFocus' analysis, SILO Pharma (SILO) is currently considered Possible Value Trap. The stock's GF Value™ is $3.44, compared to a current price of $2.10 — trading 39% below its estimated fair value. The current Total Stockholders Equity is $4.89 Mil. SILO Pharma's overall GF Score™ is 42/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For SILO Pharma (SILO), the current Total Stockholders Equity is $4.89 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SILO Pharma (SILO) Overvalued in 2026?

Based on GuruFocus' analysis, SILO Pharma stock appears to be undervalued. The current stock price of $2.10 is trading 39% below its estimated GF Value™ of $3.44. GuruFocus considers SILO Pharma to be Possible Value Trap.

Key valuation signals for SILO:

  • Total Stockholders Equity: $4.89 Mil
  • GF Value™: $3.44 vs. price of $2.10 (39% below fair value)
  • GF Score™: 42/100 with 3 warning signs

No single metric tells the full story. See the SILO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SILO Pharma Business Description

Address 677 N. Washington Boulevard, Sarasota, FL, USA, 34236
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.
42GF Score

Get the complete analysis for SILO

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.10
Price
$3.44
GF Value